Browse Prior Art Database

New crystalline form of 2-(2-aminopropan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide

IP.com Disclosure Number: IPCOM000200717D
Publication Date: 2010-Oct-26
Document File: 3 page(s) / 46K

Publishing Venue

The IP.com Prior Art Database

This text was extracted from a PDF file.
This is the abbreviated version, containing approximately 65% of the total text.

Page 01 of 3

New crystalline form of 2-(2-aminopropan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1- methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide

    2-(2-aminopropan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6- dihydropyrimidine-4-carboxamide of formula RLT-9, having the following chemical structure:

O

OH

F

N

H2N

H

N

N

O

RLT-9

is an intermediate in the preparation of N-(2-(4-(4-fluorobenzylcarbamoyl) -5- hydroxy-1-methyl-6-oxo-1, 6-dihydropyrimidin-2-yl)propan-2-yl) -5-methyl-1,3,4- oxadiazole-2- carboxamide potassium salt, known as RLT-K. RLT-K of the following chemical structure:

O

OK

F

N

N

N

H

N

O

H

N

O

N

O

is an antiretroviral drug used to treat HIV infection.

Crystalline form of RLT-9 was found and is described herein below.

   Crystalline form of RLT-9 is characterized by data selected from a powder XRD pattern with peaks at 5.2, 14.3, 15.5, 17.7, 20.3 and 25.0 degrees two theta ± 0.2 degrees two-theta; a PXRD pattern depicted in Figure 1; and combination thereof.

Figure 1: a PXRD pattern of crystalline RLT-9 obtained by example 1.


Page 02 of 3

   Crystalline form of RLT-9 may be further characterized by the X-ray powder diffraction pattern having additional peaks at 11.3, 12.5, 16.5, 19.2, 20.9 and 21.5 degrees two theta ±
0.2 degrees two theta.

   The X-ray powder diffractions were performed on a Philips X'Pert PRO powder diffractometerwiththe following parameters:

Sample holder preparation  Sample is applied directly on silicon

                 PW1817/32 "zero background" holder  In...